Moderna, Inc.MRNA
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $2.23B, declining 30.0% year-over-year. TTM net income stood at $-3.19B (4.9% growth). Quarterly EBITDA was $-1.33B and operating income was $-1.39B. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze MRNA growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters